Related Experiment Video
Updated: Jun 10, 2026
08:55
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
Annular leukocytoclastic vasculitis associated with sorafenib administration
David J Najarian1, Vathani Packianathan, Nathalie C Zeitouni
1Department of Dermatology, University of Medicine and Dentistry of New Jersey, Somerset, NJ 08873, USA. djn6uuu@gmail.com
Journal of Drugs in Dermatology : JDD
|July 22, 2010
Summary
This study reports the first case of annular leukocytoclastic vasculitis (LCV) associated with sorafenib, a targeted cancer therapy. This rare adverse event highlights the need for vigilance in patients receiving sorafenib treatment.
Area of Science:
- Oncology
- Dermatology
- Rheumatology
Background:
- Sorafenib is a multi-kinase inhibitor used in cancer treatment.
- Vasculitis is a known, though rare, potential side effect of certain medications.
- Previous literature documented only one instance of vasculitis linked to sorafenib.
Observation:
- The authors present a novel case of a patient developing annular leukocytoclastic vasculitis (LCV).
- This specific type of vasculitis was observed following the administration of sorafenib.
Findings:
- This case represents the first documented instance of annular leukocytoclastic vasculitis (LCV) specifically attributed to sorafenib.
- The findings expand the known spectrum of dermatological adverse events associated with sorafenib therapy.
Implications:
- Increased awareness of this rare sorafenib-induced vasculitis is crucial for clinicians.
- Prompt recognition and management of LCV may improve patient outcomes during sorafenib treatment.
- Further pharmacovigilance studies are warranted to understand the incidence and risk factors for sorafenib-associated vasculitis.
Related Concept Videos
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:24Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...